IMPACT Vector Logo FINAL-05.png

The IMPACT Team 

Learning How COVID-19 Affects Blood Cancer Risks

The IMPACT Study is run by a dedicated team of collaborators who develop new and

improved approaches to preventing and treating patients with early phases of blood cancers.    

By pooling their knowledge and resources, they're working together to make rapid progress, and move therapies and treatments from the laboratory to doctors’ offices, where they can benefit patients.

Irene Ghobrial, MD Principal Investigator

Dana-Farber Cancer Institute

Irene Ghobrial, MD

Principal Investigator

Catherine Marinac, PhD Dana-Farber Cancer Institute

Catherine Marinac, PhD

Co-Investigator

Dana-Farber Cancer Institute

Jeannie Calcano Peare, Dana-Farber Cancer Institute

Jeannie Calcano Peare 

Dana-Farber Cancer Institute

Nader Shayegh

Research Project Manager

Dana-Farber Cancer Institute

Nader Shayegh, Dana-Farber Cancer Institute
Allison Higgins, Dana Farber Cancer Institute

Dana-Farber Cancer Institute

Allison Higgins

Project Manager

Courtney Hamilton, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Courtney Hamilton

Project Manager

Julia Amstutz, Dana-Farber Cancer Institute

Julia Amstutz

Clinical Research Coordinator

Dana-Farber Cancer Institute

Alex Savell

Program Manager

Dana-Farber Cancer Institute

Alex Savell, Dana-Farber Cancer Institute
Erica Horowitz.jpg

Dana-Farber Cancer Institute

Erica Horowitz

Clinical Research Coordinator

maya davis.JPG

Dana-Farber Cancer Institute

Maya Davis

Clinical Research Coordinator

We're on a mission to stop blood cancer before it starts.  Join us!